252 related articles for article (PubMed ID: 10952476)
21. Pharmacokinetics and pharmacodynamics of twenty-four-hourly Kapanol compared to twelve-hourly MS Contin in the treatment of severe cancer pain.
Gourlay GK; Cherry DA; Onley MM; Tordoff SG; Conn DA; Hood GM; Plummer JL
Pain; 1997 Feb; 69(3):295-302. PubMed ID: 9085304
[TBL] [Abstract][Full Text] [Related]
22. Concentrations of morphine and morphine metabolites in CSF and plasma during continuous subcutaneous morphine administration in cancer pain patients.
Wolff T; Samuelsson H; Hedner T
Pain; 1996 Dec; 68(2-3):209-16. PubMed ID: 9121807
[TBL] [Abstract][Full Text] [Related]
23. Effect of P-glycoprotein modulation on the clinical pharmacokinetics and adverse effects of morphine.
Drewe J; Ball HA; Beglinger C; Peng B; Kemmler A; Schächinger H; Haefeli WE
Br J Clin Pharmacol; 2000 Sep; 50(3):237-46. PubMed ID: 10971308
[TBL] [Abstract][Full Text] [Related]
24. The effect of old age on the disposition and antinociceptive response of morphine and morphine-6 beta-glucuronide in the rat.
Van Crugten JT; Somogyi AA; Nation RL; Reynolds G
Pain; 1997 Jun; 71(2):199-205. PubMed ID: 9211481
[TBL] [Abstract][Full Text] [Related]
25. Disposition of morphine and its glucuronide metabolites after oral and rectal administration: evidence of route specificity.
Babul N; Darke AC
Clin Pharmacol Ther; 1993 Sep; 54(3):286-92. PubMed ID: 8375123
[TBL] [Abstract][Full Text] [Related]
26. Population pharmacokinetics of oral morphine and its glucuronides in children receiving morphine as immediate-release liquid or sustained-release tablets for cancer pain.
Hunt A; Joel S; Dick G; Goldman A
J Pediatr; 1999 Jul; 135(1):47-55. PubMed ID: 10393603
[TBL] [Abstract][Full Text] [Related]
27. Routine drug monitoring of serum concentrations of morphine, morphine-3-glucuronide and morphine-6-glucuronide do not predict clinical observations in cancer patients.
Klepstad P; Borchgrevink PC; Dale O; Zahlsen K; Aamo T; Fayers P; Fougner B; Kaasa S
Palliat Med; 2003 Dec; 17(8):679-87. PubMed ID: 14694919
[TBL] [Abstract][Full Text] [Related]
28. Morphine metabolites.
Christrup LL
Acta Anaesthesiol Scand; 1997 Jan; 41(1 Pt 2):116-22. PubMed ID: 9061094
[TBL] [Abstract][Full Text] [Related]
29. Plasma levels of morphine and morphine glucuronides in the treatment of cancer pain: relationship to renal function and route of administration.
Peterson GM; Randall CT; Paterson J
Eur J Clin Pharmacol; 1990; 38(2):121-4. PubMed ID: 2338107
[TBL] [Abstract][Full Text] [Related]
30. Bioavailability of a morphine suppository is increased after intracolostomal administration in colostoma-constructed rabbits.
Nagasawa K; Kintsuji S; Nakanishi H; Nagai K; Fujimoto S
Int J Pharm; 2003 Oct; 265(1-2):65-73. PubMed ID: 14522119
[TBL] [Abstract][Full Text] [Related]
31. Plasma morphine-3-glucuronide, morphine-6-glucuronide and morphine concentrations in patients receiving long-term epidural morphine.
Schneider JJ; Ravenscroft PJ; Cavenagh JD; Brown AM; Bradley JP
Br J Clin Pharmacol; 1992 Nov; 34(5):431-3. PubMed ID: 1467139
[TBL] [Abstract][Full Text] [Related]
32. A Compartmental Analysis for Morphine and Its Metabolites in Young Children After a Single Oral Dose.
Velez de Mendizabal N; Jimenez-Mendez R; Cooke E; Montgomery CJ; Dawes J; Rieder MJ; Aleksa K; Koren G; Jacobo-Cabral CO; Gonzalez-Ramirez R; Castañeda-Hernandez G; Carleton BC
Clin Pharmacokinet; 2015 Oct; 54(10):1083-90. PubMed ID: 25773480
[TBL] [Abstract][Full Text] [Related]
33. Morphine glucuronide-to-morphine plasma ratios are unaffected by the UGT2B7 H268Y and UGT1A1*28 polymorphisms in cancer patients on chronic morphine therapy.
Holthe M; Klepstad P; Zahlsen K; Borchgrevink PC; Hagen L; Dale O; Kaasa S; Krokan HE; Skorpen F
Eur J Clin Pharmacol; 2002 Aug; 58(5):353-6. PubMed ID: 12185559
[TBL] [Abstract][Full Text] [Related]
34. Twice-daily versus once-daily morphine sulphate controlled-release suppositories for the treatment of cancer pain. A randomized controlled trial.
Bruera E; Belzile M; Neumann CM; Ford I; Harsanyi Z; Darke A
Support Care Cancer; 1999 Jul; 7(4):280-3. PubMed ID: 10423055
[TBL] [Abstract][Full Text] [Related]
35. The bioavailability of morphine in controlled-release 30-mg tablets per rectum compared with immediate-release 30-mg rectal suppositories and controlled-release 30-mg oral tablets.
Kaiko RF; Fitzmartin RD; Thomas GB; Goldenheim PD
Pharmacotherapy; 1992; 12(2):107-13. PubMed ID: 1570227
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetics of morphine and its glucuronidated metabolites in burn injuries.
Perreault S; Choinière M; du Souich PB; Bellavance F; Beauregard G
Ann Pharmacother; 2001 Dec; 35(12):1588-92. PubMed ID: 11793627
[TBL] [Abstract][Full Text] [Related]
37. An observational study examining the effects of a surgically induced inflammatory response on the distribution of morphine and its metabolites into cerebrospinal fluid.
Wang Y; Goralski KB; Roberts DJ; Landry K; Issa ME; Sleno L; Julien LC; Wood J; Hall RI
Can J Anaesth; 2017 Oct; 64(10):1009-1022. PubMed ID: 28710563
[TBL] [Abstract][Full Text] [Related]
38. High levels of morphine-6-glucuronide in street heroin addicts.
Antonilli L; Semeraro F; Suriano C; Signore L; Nencini P
Psychopharmacology (Berl); 2003 Nov; 170(2):200-4. PubMed ID: 12774191
[TBL] [Abstract][Full Text] [Related]
39. Plasma concentrations and renal clearance of morphine, morphine-3-glucuronide and morphine-6-glucuronide in cancer patients receiving morphine.
Somogyi AA; Nation RL; Olweny C; Tsirgiotis P; van Crugten J; Milne RW; Cleary JF; Danz C; Bochner F
Clin Pharmacokinet; 1993 May; 24(5):413-20. PubMed ID: 8504624
[TBL] [Abstract][Full Text] [Related]
40. Start of oral morphine to cancer patients: effective serum morphine concentrations and contribution from morphine-6-glucuronide to the analgesia produced by morphine.
Klepstad P; Kaasa S; Borchgrevink PC
Eur J Clin Pharmacol; 2000 Jan; 55(10):713-9. PubMed ID: 10663448
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
